| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Taco R Werkman, Andrew C McCreary, Chris G Kruse, Wytse J Wadma. NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig. Synapse (New York, N.Y.). vol 65. issue 8. 2011-10-18. PMID:21218451. |
in vitro midbrain slice preparations of both species were used to record (extracellularly) the firing rates of dopamine neurons located in the substantia nigra (sn) and ventral tegmental area (vta). |
2011-10-18 |
2023-08-12 |
rat |
| Ewa Bromek, Anna Haduch, Krystyna Gołembiowska, Władysława A Danie. Cytochrome P450 mediates dopamine formation in the brain in vivo. Journal of neurochemistry. vol 118. issue 5. 2011-10-14. PMID:21651557. |
in model a, quinine (a cyp2d inhibitor) given intraperitoneally caused a significant decrease in dopamine level in the striatum and nucleus accumbens and tended to fall in the substantia nigra and frontal cortex. |
2011-10-14 |
2023-08-12 |
rat |
| Aditiben Patel, Giuseppe V Toia, Kalea Colletta, Brinda Desai Bradaric, Paul M Carvey, Bill Hende. An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity. Experimental neurology. vol 231. issue 1. 2011-10-13. PMID:21703263. |
we previously demonstrated that several dopamine (da) neurotoxins produced punctate areas of fitc-labeled albumin (fitc-la) leakage in the substantia nigra and striatum suggesting blood brain barrier (bbb) dysfunction. |
2011-10-13 |
2023-08-12 |
mouse |
| Mickael Decressac, Ayse Ulusoy, Bengt Mattsson, Biljana Georgievska, Marina Romero-Ramos, Deniz Kirik, Anders Björklun. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain : a journal of neurology. vol 134. issue Pt 8. 2011-10-13. PMID:21712347. |
we found that viral vector-mediated delivery of glial cell line-derived neurotrophic factor into substantia nigra and/or striatum, administered 2-3 weeks before α-synuclein, was inefficient in preventing the wild-type α-synuclein-induced loss of dopamine neurons and terminals. |
2011-10-13 |
2023-08-12 |
human |
| C V Fontanilla, Z Ma, X Wei, J Klotsche, L Zhao, P Wisniowski, R C Dodel, M R Farlow, W H Oertel, Y D. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience. vol 188. 2011-10-12. PMID:21571045. |
parkinson's disease is associated with the loss of dopaminergic neurons in the substantia nigra and decreased striatal dopamine levels. |
2011-10-12 |
2023-08-12 |
mouse |
| Alix B W Norton, Yong Sang Jo, Emily W Clark, Cortney A Taylor, Sheri J Y Mizumor. Independent neural coding of reward and movement by pedunculopontine tegmental nucleus neurons in freely navigating rats. The European journal of neuroscience. vol 33. issue 10. 2011-09-26. PMID:21395868. |
phasic firing of dopamine (da) neurons in the ventral tegmental area (vta) and substantia nigra (sn) is likely to be crucial for reward processing that guides learning. |
2011-09-26 |
2023-08-12 |
rat |
| M Flint Bea. Neuroprotective effects of creatine. Amino acids. vol 40. issue 5. 2011-09-15. PMID:21448659. |
creatine produced dose-dependent neuroprotective effects against mptp toxicity reducing the loss of dopamine within the striatum and the loss of dopaminergic neurons in the substantia nigra. |
2011-09-15 |
2023-08-12 |
mouse |
| Hui-Ming Gao, Jau-Shyong Hon. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Progress in neurobiology. vol 94. issue 1. 2011-09-08. PMID:21439347. |
the gradual, irreversible loss of dopamine neurons in the substantia nigra is the signature lesion of pd. |
2011-09-08 |
2023-08-12 |
Not clear |
| Zhen-Hua Gui, Jian Liu, Yong Wang, Umar Ali, Tao Wang, Li Che. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons. The Chinese journal of physiology. vol 54. issue 2. 2011-08-18. PMID:21789890. |
effects of chronic, systemic treatment with the dopamine receptor agonist r-apomorphine in partially lesioned rat model of parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons. |
2011-08-18 |
2023-08-12 |
rat |
| Zhanyun Lv, Hong Jiang, Huamin Xu, Ning Song, Junxia Xi. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 3. 2011-08-16. PMID:20556443. |
the staging of lewy-related pathology in sporadic parkinson's disease (pd) reveals that many brain nuclei are affected in pd during different stages, except the ventral tegmental area (vta), which is close related to the substantia nigra (sn) and enriched in dopamine (da) neurons. |
2011-08-16 |
2023-08-12 |
mouse |
| Thomas Carlsson, Friederike R Schindler, Matthias Höllerhage, Candan Depboylu, Oscar Arias-Carrión, Stefan Schnurrbusch, Thomas W Rösler, Wojciech Wozny, Gerhard P Schwall, Karlfried Groebe, Wolfgang H Oertel, Patrik Brundin, André Schrattenholz, Günter U Höglinge. Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of neurochemistry. vol 117. issue 6. 2011-08-03. PMID:21517849. |
we observed that systemic injections of the extracellular domain of nrg1β(1) (nrg1β(1)-ecd) increased dopamine levels in the substantia nigra and striatum of adult mice. |
2011-08-03 |
2023-08-12 |
mouse |
| M Kathleen Borland, Patricia A Trimmer, Jeremy D Rubinstein, Paula M Keeney, Kp Mohanakumar, Lei Liu, James P Bennet. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Molecular neurodegeneration. vol 3. 2011-07-14. PMID:19114014. |
rostral progression into substantia nigra with death of dopamine neurons produces the motor impairment phenotype that yields a clinical diagnosis. |
2011-07-14 |
2023-08-12 |
Not clear |
| Torsten Falk, Shiling Zhang, Scott J Sherma. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Molecular neurodegeneration. vol 4. 2011-07-14. PMID:20003314. |
parkinson's disease (pd) results from the degeneration of dopaminergic neurons in the substantia nigra and the consequent deficit of dopamine released in the striatum. |
2011-07-14 |
2023-08-12 |
rat |
| Markos Poulopoulos, Cheryl Water. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core evidence. vol 5. 2011-07-14. PMID:20694135. |
in the 1960s, it was shown that the degeneration of dopamine producing neurons in the substantia nigra (sn) caused the motor features of pd. |
2011-07-14 |
2023-08-12 |
Not clear |
| Frederick P Bellinger, Miyoko T Bellinger, Lucia A Seale, Andrea S Takemoto, Arjun V Raman, Takanori Miki, Amy B Manning-Boğ, Marla J Berry, Lon R White, G Webster Ros. Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. Molecular neurodegeneration. vol 6. issue 1. 2011-07-14. PMID:21255396. |
parkinson's disease is a neurodegenerative disorder characterized pathologically by the loss of nigrostriatal dopamine neurons that project from the substantia nigra in the midbrain to the putamen and caudate nuclei, leading to the clinical features of bradykinesia, rigidity, and rest tremor. |
2011-07-14 |
2023-08-12 |
Not clear |
| Tahira Farooqui, Akhlaq A Farooqu. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinson's disease. vol 2011. 2011-07-14. PMID:21403820. |
pd is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, depletion of dopamine in the striatum, abnormal mitochondrial and proteasomal functions, and accumulation of α-synuclein that may be closely associated with pathological and clinical abnormalities. |
2011-07-14 |
2023-08-12 |
Not clear |
| Penny A Macdonald, Oury Monch. Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinson's disease. vol 2011. 2011-07-14. PMID:21437185. |
whereas dorsal striatum receives dopamine input from the substantia nigra (sn), ventral striatum is innervated by dopamine-producing cells in the ventral tegmental area (vta). |
2011-07-14 |
2023-08-12 |
Not clear |
| Dawn Béraud, Margaret Twomey, Benjamin Bloom, Andrew Mittereder, Vy Ton, Katherine Neitzke, Sergey Chasovskikh, Timothy R Mhyre, Kathleen A Maguire-Zeis. α-Synuclein Alters Toll-Like Receptor Expression. Frontiers in neuroscience. vol 5. 2011-07-14. PMID:21747756. |
parkinson's disease, an age-related neurodegenerative disorder, is characterized by the loss of dopamine neurons in the substantia nigra, the accumulation of α-synuclein in lewy bodies and neurites, and neuroinflammation. |
2011-07-14 |
2023-08-12 |
mouse |
| W Michael Panneton, V B Kumar, Qi Gan, William J Burke, James E Galvi. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PloS one. vol 5. issue 12. 2011-07-05. PMID:21179455. |
we examined the consequences of injections of 3,4-dihydroxyphenylacetaldehyde (dopal), a toxic metabolite of dopamine, into the substantia nigra of rats on motor behavior and neuronal survival. |
2011-07-05 |
2023-08-12 |
rat |
| James B Koprich, Tom H Johnston, Philippe Huot, M Gabriela Reyes, Maria Espinosa, Jonathan M Brotchi. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PloS one. vol 6. issue 3. 2011-07-05. PMID:21408191. |
the pathological hallmarks of parkinson's disease (pd) are degeneration of dopamine (da) neurons of the substantia nigra (sn) and the presence of alpha-synuclein (α-syn)-rich lewy bodies in da cells that remain. |
2011-07-05 |
2023-08-12 |
rat |